May 5, 2020
Vifor Pharma’s partner Akebia with positive cardiovascular outcomes program testing vadadustat,
Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Akebia
March 18, 2019
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
Akebia has substantial revenue growth opportunity for Auryxia following robust2018 ommercial performance, while the first regulatory submission for vadadustat expected in 2019 inJapan, following positive top-line results from pivotal phase 3 studiesin Japanese subjects with anemia due to chronic kidney disease